| Pair Name | Withaferin A, Sorafenib | ||
| Phytochemical Name | Withaferin A (PubChem CID: 265237 ) | ||
| Anticancer drug Name | Sorafenib (PubChem CID: 216239 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Withaferin A, Sorafenib | |||
| Disease Info | [ICD-11: 2D10.Z] | Thyroid cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Phosphorylation | CASP3 | hsa836 |
| Down-regulation | Expression | PARP1 | hsa142 | |
| In Vitro Model | B-CPAP | Poorly differentiated thyroid gland carcinoma | Homo sapiens (Human) | CVCL_0153 |
| SW1736 | Thyroid gland anaplastic carcinoma | Homo sapiens (Human) | CVCL_3883 | |
| Result | Combination therapy with sorafenib + withaferin showed synergistic efficacy in papillary and anaplastic cancers in vitro with significant induction of apoptosis. This combination achieved potent anticancer activity with lower overall doses of sorafenib, indicating a potential strategy to decrease sorafenib toxicity in future translational studies. | |||
| No. | Title | Href |
|---|---|---|
| 1 | A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers. Am J Surg. 2012 Dec;204(6):895-900; discussion 900-1. doi: 10.1016/j.amjsurg.2012.07.027. | Click |
